Related Experiment Video

Updated: Oct 9, 2026

Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy
08:26

Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy

Published on: January 11, 2016

12.2K

Plasma bisphenol a and phthalate levels in children with cerebral palsy: a case-control study

Özlem Tezol1, Sıddıka Songül Yalçin2, Anıl Yirün3,4

  • 1Department of Pediatrics, Faculty of Medicine, Mersin University, Mersin, Turkey.

International Journal of Environmental Health Research
|December 15, 2022
PubMed

Insights

Children with cerebral palsy (CP) showed lower levels of certain phthalates, DEHP and MEHP, compared to controls. Exposure sources for BPA and phthalates differ between these groups.

Area of Science:

  • Environmental Health
  • Pediatric Neurology
  • Toxicology

Background:

  • Bisphenol A (BPA) and phthalates are common endocrine-disrupting chemicals.
  • Exposure to these chemicals is widespread in the general population.
  • Previous studies have not extensively investigated BPA and phthalate exposure in children with cerebral palsy (CP).

Purpose of the Study:

  • To compare plasma concentrations of BPA, DEHP, MEHP, and DBP in children with CP and healthy controls.
  • To identify potential sources of BPA and phthalate exposure in children with CP.

Main Methods:

  • A case-control study involving 68 children with CP and 70 healthy controls.
  • Analysis of blood samples for BPA, di-(2-ethylhexyl)-phthalate (DEHP), mono-(2-ethylhexyl)-phthalate (MEHP), and dibutyl phthalate (DBP) concentrations.
  • Assessment of potential exposure sources including food containers, personal care products, household cleaners, heating methods, and water supply.

Main Results:

  • Plasma concentrations of BPA and dibutyl phthalate (DBP) were similar between children with CP and controls.
  • Median levels of DEHP and MEHP were significantly lower in children with CP compared to controls (p=0.035 and p<0.001, respectively).
  • Specific exposure sources, such as plastic food containers, personal care products, and household cleaners, were associated with higher BPA and phthalate levels in children with CP.

Conclusions:

  • Potential exposure sources for BPA and phthalates differ between children with CP and healthy controls.
  • Children with CP are not exposed to higher levels of BPA and phthalates overall, with some phthalate levels being lower.
  • Further research is warranted to understand the specific exposure pathways and their implications for CP.

Keywords:
BPACerebral palsychildrenphthalate

More Related Videos

Assessment of the Effects of Endocrine Disrupting Compounds on the Development of Vertebrate Neural Network Function Using Multi-electrode Arrays08:28

Assessment of the Effects of Endocrine Disrupting Compounds on the Development of Vertebrate Neural Network Function Using Multi-electrode Arrays

Published on: April 26, 2018

6.1K
Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

6.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...